Debrisoquine oxidation polymorphism in a Tasmanian population.
The debrisoquine hydroxylation phenotype was studied in 152 unselected healthy Tasmanian subjects, who were mostly Caucasians of British ancestry. Following a 10 mg oral dose of debrisoquine (D), the ratio of D/4-hydroxydebrisoquine excreted in 8-h urine (metabolic ratio, MR) was determined. MR values were bimodally distributed. Thirteen subjects (8.6%) had MR values from 13.8 to 93.3 and were considered to be poor metabolisers of D, while the others were extensive metabolisers with MR values of 0.04 to 5.4. The D hydroxylation phenotype was not associated with sex. These findings confirm the constancy of D polymorphism in a Caucasian population even after migration to another country.
Veronese
M E
ME
School of Pharmacy, University of Tasmania, Hobart, Australia.
McLean
S
S
D000293:Adolescent; D000328:Adult; D001315:Australia; D003647:Debrisoquin / Q000031:analogs & derivatives / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic; D044465:White People
C012359:4-hydroxydebrisoquin; D003647:Debrisoquin